ArticlePLoS neglected tropical diseases2026
Mass drug administration for soil-transmitted helminthiasis and schistosomiasis in selected districts of Rwanda: Coverage, implementation factors, and household water, sanitation, and hygiene conditions.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Rwanda, about 1 in 3 people are affected by soil-transmitted helminthiases (38.7%) and 1 in 4 by schistosomiasis in high-risk areas (27.2% by point-of-care circulating cathodic antigen), both associated with poor water, sanitation, and hygiene (WASH). Mass drug administration (MDA) is the primary control strategy, but reported coverage may not reflect true reach. This study assessed MDA coverage of albendazole/mebendazole and praziquantel in selected districts, identified reasons for non-reach, examined factors associated with uptake, and described household WASH conditions.
methodsA cross-sectional, community-based survey was conducted in five purposively selected districts using a stratified cluster design. Survey-weighted estimates summarized treatment reach (offered the drug), uptake (swallowed the drug), and household WASH conditions. Survey-weighted logistic regression was used to identify individual and implementation factors associated with uptake.
resultsAlbendazole/mebendazole uptake was 91.9% (95% CI: 84.3-96.0), closely matching reported coverage of 96%. The main reasons for non-reach were drug stockouts (23.7%), absence during MDA (15.8%), and unwillingness to take the drug (15.2%). Praziquantel uptake was 88.0% (95% CI: 78.7-93.6), consistent with reported coverage of 80%. For praziquantel, unwillingness to take tablets (29.6%) and absence during MDA (14.4%) were the most common reasons for non-reach. Receiving sufficient information about MDA to make an informed decision was associated with higher odds of uptake for both ALB/MBZ (adjusted odds ratios [aOR]: 5.17, 95% CI: 2.01-13.27) and PZQ (aOR: 3.58, 95% CI: 1.33-9.64). For ALB/MBZ, finding MDA participation easy (aOR: 11.41, 95% CI: 2.59-50.16), feeling comfortable with the MDA distributor (aOR: 10.05, 95% CI: 2.43-41.47), and feeling comfortable with the MDA location (aOR: 3.23, 95% CI: 1.25-8.39) were each independently associated with higher uptake. For PZQ, males had significantly higher odds of uptake compared to females (aOR: 2.64, 95% CI: 1.15-6.07). Among households, 65.6% used improved drinking water sources, 91.4% obtained water from public places, 50.7% treated their water, 84.4% had improved toilets, 51.6% had visibly clean toilets, and 62% lacked a handwashing station.
conclusionMDA coverage in Rwanda exceeded WHO targets and closely matched reported estimates, reflecting strong implementation. Addressing remaining gaps in drug supply, MDA communication, and WASH infrastructure will be important to sustain and strengthen control of soil-transmitted helminthiases and schistosomiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.